Sign in

CIK 0001819133

  • Non-accelerated filer
  • Smaller reporting company

Tango Therapeutics, Inc.

Sign in to watch
Ticker
TNGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-320-4900
Business address
201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
Former names
BCTG Acquisition Corp.
  1. 3 Insider Initial Statement of Ownership
  2. 4 Planned sale President, R&D sold 38,460 shares at $25.00 ($961,500)
  3. 4 Planned sale President, R&D sold 27,000 shares at $21.20 ($572,478)
  4. 4 Planned sale President, R&D sold 12,000 shares at $20.11 ($241,320)
  5. 4 Planned sale President, R&D sold 20,251 shares at $15.00 ($303,765)
  6. 4 Planned sale President, R&D sold 54,345 shares at $12.77 ($694,208)
  7. 4 Open-market sale Chief Financial Officer sold 10,317 shares at an average $12.26 ($126,531)
  8. 4 Open-market sale Director, Executive Chair sold 30,519 shares at an average $12.26 ($374,294)
  9. 4 Open-market sale President, R&D sold 18,452 shares at an average $12.26 ($226,300)
  10. 4 Grant or award President & CEO acquired 350,000 shares (grant or award)
  11. 4 Grant or award Director acquired 10,000 shares (grant or award)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale 10% owner sold 477,401 shares at $10.15 ($4,846,575)
  15. 4 Open-market sale 10% owner sold 500,000 shares at $8.02 ($4,008,500)
  16. 4 Open-market sale 10% owner sold 363,541 shares at $7.04 ($2,559,329)
  17. 4 Open-market sale 10% owner sold 729,365 shares at an average $7.00 ($5,108,970)
  18. 4 Open-market sale 10% owner sold 302,194 shares at $7.00 ($2,115,358)
  19. 4 Open-market sale 10% owner sold 1,100,000 shares at $7.01 ($7,712,760)
  20. 4 Grant or award Director acquired 6,250 shares (grant or award)

Page 2 of 8 · 156 filings